# US 8,277,793 B2 · Prophylactic or therapeutic agent for viral disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,793 B2
- Document ID: US8277793B2
- Status: Granted
- Kind: B2
- Application number: 12/307,726
- Filed: 2007-07-06
- Published: 2009-12-31
- Granted: 2012-10-02
- Earliest claimed: 2006-07-07
- Assignees: Meiji Seika Pharma Co., Ltd.
- Inventors: Yoichi Hiasa; Hiroyuki Kuzuhara
- Web page: https://patentgrep.com/patent/US8277793B2

## CPC

- A61K 38/21: Interferons {[IFN]}
- A61K 31/075: Ethers or acetals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A prophylactic or therapeutic agent for a viral disease, characterized by combining 22β-methoxyolean-12-ene-3β,24(4β)-diol with an interferon as active ingredients is disclosed. The prophylactic or therapeutic agent of the present invention exhibits a high therapeutic effect by administering 22β-methoxyolean-12-ene-3β,24(4β)-diol and interferon as a combination thereof.

## Claims

### Claim 1

A pharmaceutical composition, comprising 22β-methoxyolean-12-ene-3β,24(4β)-diol and an interferon α.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the interferon α is at least one IFNα selected from the group consisting of natural IFNα, IFNα-2a, IFNα-2b, PEG-natural IFNα, PEG-IFNα-2a and PEG-IFNα-2b.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is a single preparation comprising the combination of 22β-methoxyolean-12-ene-3β,24(4β)-diol and the interferon α.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is a combination of a first single preparation comprising the 22β-methoxyolean-12-ene-3β,24(4β)-diol and a second single preparation comprising the interferon α.

### Claim 5 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the 22β-methoxyolean-12-ene-3β,24(4β)-diol and the interferon α are in a combination ratio from 1 mg:100,000 I.U. to 1000 mg:10,000,000 I.U.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the 22β-methoxyolean-12-ene-3β,24(4β)-diol and the interferon α are in a combination ratio from 25 mg:1,000,000 I.U. to 800 mg:10,000,000 I.U.
